BI
OVID icon

BVF Inc’s Ovid Therapeutics OVID Stock Holding History

BVF Inc’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,853,818
Closed -$1.27M – 48
2025
Q2 		$1.27M Hold
3,853,818
– – 0.05% 42
2025
Q1 		$1.2M Hold
3,853,818
– – 0.05% 49
2024
Q4 		$3.6M Hold
3,853,818
– – 0.12% 45
2024
Q3 		$4.55M Hold
3,853,818
– – 0.13% 43
2024
Q2 		$2.96M Hold
3,853,818
– – 0.08% 48
2024
Q1 		$11.8M Sell
3,853,818
-2,997,233
-44% -$10M 0.32% 38
2023
Q4 		$22.1M Hold
6,851,051
– – 0.55% 37
2023
Q3 		$26.3M Hold
6,851,051
– – 0.71% 31
2023
Q2 		$22.5M Hold
6,851,051
– – 0.63% 32
2023
Q1 		$17.7M Hold
6,851,051
– – 0.65% 42
2022
Q4 		$12.7M Hold
6,851,051
– – 0.54% 46
2022
Q3 		$12.6M Hold
6,851,051
– – 0.52% 49
2022
Q2 		$14.7M Hold
6,851,051
– – 0.71% 39
2022
Q1 		$21.5M Buy
6,851,051
+220,000
+3% +$692K 0.86% 34
2021
Q4 		$21.3M Hold
6,631,051
– – 0.77% 38
2021
Q3 		$22.3M Hold
6,631,051
– – 0.87% 33
2021
Q2 		$25.9M Buy
6,631,051
+213,500
+3% +$843K 0.97% 26
2021
Q1 		$25.8M Buy
6,417,551
+1,895,500
+42% +$6.3M 0.97% 29
2020
Q4 		$10.4M Buy
4,522,051
+900,000
+25% +$4.19M 0.41% 44
2020
Q3 		$20.8M Buy
3,622,051
+1,229,900
+51% +$8.23M 1.13% 30
2020
Q2 		$17.6M Buy
2,392,151
+1,106,147
+86% +$5.17M 1.09% 28
2020
Q1 		$3.83M Buy
1,286,004
+551,703
+75% +$1.86M 0.36% 43
2019
Q4 		$3.05M Sell
734,301
-1,586,935
-68% -$5.01M 0.23% 48
2019
Q3 		$7.52M Sell
2,321,236
-1,262,000
-35% -$2.87M 0.79% 37
2019
Q2 		$6.63M Buy
3,583,236
+290,236
+9% +$518K 0.72% 38
2019
Q1 		$5.83M Buy
+3,293,000
New +$8.24M 0.65% 41

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BVF Inc's OVID Position: Q3 2025 in Review

BVF Inc sold out of Ovid Therapeutics (OVID) in Q3 2025, closing a stake of 3,853,818 shares — an estimated $1.27M sold.

BVF Inc first reported a position in OVID in Q1 2019 and held it in 26 quarters. The position peaked at $26.3M in Q3 2023. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

  • BVF Inc reported no remaining Ovid Therapeutics position as of Q3 2025 after selling out during the quarter.
  • BVF Inc sold 3,853,818 Ovid Therapeutics shares in Q3 2025, an estimated $1.27M.
  • BVF Inc first reported a position in Ovid Therapeutics in Q1 2019 and held it in 26 quarters.
  • BVF Inc's Ovid Therapeutics position peaked at $26.3M in Q3 2023.
  • 81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on BVF Inc's 13F filing for Q3 2025, filed 14 Nov 2025.